Geron Corp. buy melinda
Start price
03.09.12
/
50%
€2.25
Target price
04.03.13
€2.80
Performance (%)
-51.11%
End price
04.03.13
€1.10
Summary
This prediction ended on 04.03.13 with a price of €1.10. The BUY prediction by melinda for Geron Corp. performed very badly with a performance of -51.11%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | -0.745% | -0.745% | 1.361% | -52.494% |
| iShares Core DAX® | 0,44 % | 5,64 % | 7,81 % | 63,64 % |
| iShares Nasdaq 100 | 1,06 % | 0,28 % | 27,24 % | 88,12 % |
| iShares Nikkei 225® | 1,77 % | 0,41 % | 49,27 % | 83,53 % |
| iShares S&P 500 | 0,37 % | 1,92 % | 22,34 % | 68,75 % |
Comments by melinda for this prediction
In the thread Geron Corp. diskutieren
pharma
Geron Corp ist ein biopharmazeutisches Unternehmen, das therapeutische Klasse für Krebs entwickelt (Brust, Lunge)
(Laufzeit überschritten)